Determination of the Risk Factors in Patients Admitted with Bleeding Due to Warfarin use and Evaluation of the Current Bleeding Risk Scores

Year 2022, , 330 - 335, 14.03.2022

Aykut Demirkıran A Basturk Şamil Ecirli

https://doi.org/10.20515/otd.982588

Abstract

Warfarin is the most common drug used in oral anticoagulation. The most serious side effect is bleeding. The aim of this study is to determine the risk factors that increase bleeding. In this retrospective study, we evaluated 283 patients with the diagnosis of bleeding due to warfarin use. The patients were divided into two groups as major and minor bleeding according to the need for blood transfusion. Age, gender, international normalized ratio (INR) level, drug use history, presence of additional disease, duration of treatment, warfarin dosage and laboratory data were obtained from patient files. Bleeding risk scores of 197 patients for whom laboratory data could be obtained before the bleeding event were calculated. The mean age of the patients was 69.16 ± 12.90 years. 51.9% were female and 48.1% were male. The major bleeding group was older (p=0,007). The rate of drug use that interacts with warfarin was 53.3%. Acetylsalicylic acid (ASA) usage rate was 31.4%. ASA use was more common in the major bleeding group (p=0,000). Concomitant disease was detected in 86.9% of the patients. The most common concomitant diseases were heart disease 59%, hypertension 56.5% and diabetes 21.2%, respectively. Heart disease was more common in the major bleeding group (p=0,001). The hemoglobin value measured at least one month before the bleeding was found to be significantly lower in the major bleeding group (p=0,001). Only the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) median score was significantly higher in patients experiencing major bleeding than minor bleeding (p = 0.002). In our study, it was found that major bleeding due to warfarin was associated with advanced age, ASA use, concomitant heart disease and anemia development before bleeding. Therefore, close monitoring of the bleeding profile is very important. Patients and their care providers should be well informed about the side effects of the drug.

Keywords

Warfarin, oral anticoagulation, risk of bleeding, bleeding risk scores

Varfarin Kullanımına Bağlı Kanama ile Başvuran Hastalarda Risk Faktörlerinin Belirlenmesi ve Mevcut Kanama Risk Skorlarının Değerlendirilmesi

Abstract

Varfarin oral antikoagülasyonda kullanılan en yaygın ilaçtır. En ciddi yan etkisi kanamadır. Bu çalışmanın amacı kanamayı artıran risk faktörlerini belirlemektir. Bu retrospektif çalışmada varfarin kullanımına bağlı kanama tanısı alan 283 hastayı değerlendirdik. Hastalar kan transfüzyonu ihtiyacına göre majör ve minör kanama olarak iki gruba ayrıldı. Hasta dosyalarından yaş, cinsiyet, uluslararası normalleştirilmiş oran (INR) düzeyi, ilaç kullanım öyküsü, ek hastalık varlığı, tedavi süresi, varfarin dozu ve laboratuvar verileri elde edildi. Kanama olayı öncesi laboratuvar verilerine ulaşılabilen 197 hastanın kanama risk skorları hesaplandı. Hastaların ortalama yaşı 69,16±12,90 yıldı. Majör kanama grubu daha yaşlıydı (p=0,007). %51,9 kadın, %48,1 erkek idi. Varfarinle etkileşen ilâç kullanım oranı %53,3 idi. Asetilsalisilik asit (ASA) kullanım oranı %31,4’tü. ASA kullanımı majör kanama grubunda daha yaygındı (p=0,000). Hastaların %86,9’unda eşlik eden hastalık varlığı tespit edildi. En sık eşlik eden hastalıklar sırasıyla kalp hastalığı %59, hipertansiyon %56,5 ve diyabet %21,2 olarak görüldü. Kalp hastalığı major kanama grubunda daha sıktı (p=0,001). Kanamadan en az bir ay önce bakılan hemoglobin değeri majör kanama grubunda anlamlı olarak daha düşük bulundu (p=0,001). Majör kanaması olan hastalarda minör kanamaya göre sadece ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) medyan skoru anlamlı olarak daha yüksekti (p = 0.002). Çalışmamızda varfarine bağlı majör kanamanın ileri yaş, aspirin kullanımı, eşlik eden kalp hastalığı ve kanama öncesi anemi gelişimi ile ilişkili olduğu bulundu. Bu nedenle kanama profilinin yakın takibi çok önemlidir. Hastalar ve bakım sağlayıcıları ilacın yan etkileri hakkında iyi bilgilendirilmelidir.

Keywords

Varfarin; oral antikoagulasyon; kanama riski, kanama risk skorları

References

• 1. Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison’s Principles of Internal Medicine. 20th ed. McGraw Hill; 2018.
• 2. Moyer TP, O’Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009;84:1079–94.
• 3. Goldman L. (., Schafer, A. I., & Cecil, R. L. 1. Goldman-Cecil medicine (26th edition.). Philadelphia, PA: Elsevier. 2020
• 4. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, Kitchen S, Makris M; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011 ;154:311-24.
• 5. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost. 2006 ;4:1853–63.
• 6. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91–9.
• 7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 ;285:2864–70.
• 8. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173–80.
• 9. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58:395–401.
• 10. Proietti M, Hijazi Z, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, et al.; RE-LY Investigators. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. J Intern Med. 2018;283:282–92.
• 11. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390–6.
• 12. Wallvik J, Själander A, Johansson L, Bjuhr O, Jansson JH. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care. 2007;25:123–8.
• 13. Organization WH; Health Statistics And Health İnformation Systems. WHO Mortality Database: Http://Www. Who. İnt/Whosis/Database/Mort/Table1. Cfm (Consulted 16 September 2010), 2010.
• 14. Özgenel ŞM. Varfarine Bağlı Kanamalarda Risk Faktörlerinin Karşılaştırılması. Uzmanlık Tezi; 2010.
• 15. Galatro KM, Adams PC, Cohen M, McBride R, Blanke H. Bleeding Complications and INR Control of Combined Warfarin and Low-Dose Aspirin Therapy in Patients with Unstable Angina and Non-Q-Wave Myocardial Infarction. J Thromb Thrombolysis. 1998;5:249–55.
• 16. Douketis J.D. Perioperative management of patients receiving anticoagulant or antiplatelet therapy: a clinician-oriented and practical approach. Hospital practice (1995), 2011;39:41–54.